← Back to all signals
RESEARCH PAPER ANALYSIS

Construction and validation of nomogram prognostic model for predicting survival in hepatoblastoma patients: a population-based study.

AI interpretation is pending for this paper.

Open original publication →
PMID38795309
JournalUpdates in surgery
Publication Date2024-05-25
Ingested2026-08-02 12:02 AM
EXECUTIVE SUMMARY

What the AI sees

Not AI summarized yet.

WHY IT MATTERS

Research significance

Pending deeper interpretation.

ABSTRACT

Source abstract

For patients with hepatoblastoma (HB), current staging system is not accurate in predicting survival outcomes. The aim of this study was to develop two accurate survival prediction models to guide clinical decision making. A retrospective analysis of 424 HB patients was performed from 2004 to 2015 using the Surveillance, Epidemiology and End Results (SEER) database. Univariate and multivariate Cox regression analysis was used to screen for variables. The identified variables were used to build survival prediction model. The performance of the nomogram models was assessed based on the concordance index (C-index), calibration plot, and receiver operating characteristic (ROC) curve. The Cox regression analysis identified six variables affecting overall survival (OS) in HB patients, including race, tumor size, lymph node involvement, distant metastases, surgery and chemotherapy. And the Cox regression analysis identified five variables including race, lymph node involvement, distant metastases, surgery, and chemotherapy that affect cancer-specific survival (CCS) in HB patients. In the training cohort, the C-index of the nomogram in predicting the OS was 0.791 [95% confidence intervals (95% CI) 0.717-0.865], CSS was 0.805(95% CI 0.728-0.882). In the validation cohort, the C-index of the nomogram in predicting the OS was 0.712 (95% CI 0.511-0.913), the CSS was 0.751 (95% CI 0.566-0.936). In the training cohort, the area under the receiver operator characteristics curve (AUC) values of the nomogram in prediction of the 1-, 3-, and 5-year OS were 0.842 (95% CI 0.739-0.944), 0.759 (95% CI 0.670-0.849), and 0.770 (95% CI 0.686-0.852), respectively. In the validation cohort, the AUC values for prediction of the 1-, 3-, and 5-year OS were 0.920 (95% CI 0.806-1.034), 0.863 (95% CI 0.750-0.976), and 0.844 (95% CI 0.721-0.967), respectively. Two nomogram models were developed and validated in this study which provided accurate prediction of the OS and CSS in HB patients. The constructed models can be used for predicting survival outcomes and guide treatment for HB patients.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 Pott's Puffy Tumor Mimicking Langerhans Cell Histiocytosis in a Child. Pediatrics international : official journal of the Japan Pediatric Society 28.5 2 A Population-Based Study of Pediatric and Adult Brainstem Glioma: Prognostic Nomograms for Overall and Cancer-Specific Survival. Turkish neurosurgery 62.02 3 Surgical Management of Third Ventricular Colloid Cysts: The Fate of Open Microsurgery. Turkish neurosurgery 63.5 4 Prenatal Ultrasound and MRI Findings in Two Fetuses With Perineal Lipoma. Congenital anomalies 56.0 5 Undiagnosed Undescended Testis in Young Adults in Saudi Arabia: Examination-Based Prevalence, Sociocultural Barriers to Early Care and Public Health Implications. Arab journal of urology 64.5 6 Neuro-ophthalmological disturbances in pediatric posterior fossa tumors: Prevalence, risk factors, and outcomes. Neuro-oncology advances 63.82 7 The oncology and fertility outcomes in patients with ovarian steroid cell tumors: a single center experience. Journal of ovarian research 57.5 8 Predicting brain tumour enhancement from non-contrast MRI with artificial intelligence: a multicohort, retrospective, diagnostic accuracy study. The Lancet medical imaging & theranostics 59.01 9 Correction: Clinical characteristics and risk factors of acute cutaneous graft-vs.-host disease following allogeneic hematopoietic stem cell transplantation in pediatric acute myeloid leukemia: a singlecenter retrospective study. Frontiers in pediatrics 55.0 10 Targeting IL-23p19 in Inflammatory Bowel Disease: The Road Ahead. Journal of inflammation research 57.65 11 When Three Diseases Collide: Human Immunodeficiency Virus, Hodgkin Lymphoma, and Tuberculosis in a Young Child. Pediatric pulmonology 28.5 12 Late recovery from chronic arginine vasopressin deficiency: a multicenter retrospective case-control study. Journal of the Endocrine Society 58.51 13 Early neuroendocrine signatures of polyendocrine metabolic ovarian syndrome risk: Pubertal programming, social brain signals, and novel therapeutic targets. Journal of neuroendocrinology 62.24 14 Obesity in survivors of childhood cancer. Annals of pediatric endocrinology & metabolism 55.06 15 Risk factors for recurrence in pediatric craniopharyngioma: impact of extensive tumor involvement and growth hormone therapy in a multicenter cohort. Annals of pediatric endocrinology & metabolism 63.36 16 Radiological assessment of radon concentration in drinking water from Lagos State University campus, Nigeria. Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 58.7 17 Claudin-3 as a marker of intestinal permeability and its relation to inflammatory status in adolescents with functional gastrointestinal disorders. Pediatric research 63.9 18 Reconstructing the cancer journey: The impact of adolescent and young adult (AYA) patient advisory boards on survivor experiences and advocacy. Journal of psychosocial oncology 57.0 19 Safe electrophysiology-guided resection of an epileptogenic non-exophytic hamartoma at the floor of the fourth ventricle in a child. Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 56.4 20 Desire for future children and interest in consultation with a fertility specialist among adolescent and young adult (AYA) cancer patients. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 57.35 21 Trends in Clinicopathologic Characteristics of Pediatric Differentiated Thyroid Carcinoma: A Single-Center Experience from 1995 to 2022. Endocrinology and metabolism (Seoul, Korea) 56.56 22 Modeling Wilms Tumor Development with Multiple Lineage Human Fetal Kidney Organoids Reveals the Cellular Origin and Specific Drivers of Tumorigenesis. Cancer research 48.5 23 Late effects after novel therapies for childhood cancer: Anticipating the future landscape of health outcomes for survivors. Journal of the National Cancer Institute 65.24 24 Atrophic Papulosis: A Systematic Review of Pediatric Cases. Pediatric dermatology 53.55 25 Menin inhibition in pediatric UBTF-TD myelodysplastic syndrome: molecular rationale and clinical observation. Molecular and cellular pediatrics 63.6 26 Abatacept in biologic-refractory juvenile idiopathic arthritis-associated uveitis: a case-based review. Clinical rheumatology 67.44 27 Paediatric biobanking in the era of precision medicine: ethical, regulatory, and scientific challenges from childhood to adulthood. European journal of pediatrics 53.78 28 Spinal ependymoma: a comprehensive review of molecular classification, management guidelines, and clinical outcomes with a focus on the pediatric population (Part III of ependymomas across compartments). Journal of neuro-oncology 63.57 29 Pediatric and Adult Sinonasal Phosphaturic Mesenchymal Tumors: CDKN2A Copy Number Alterations and Their Association with Recurrence. Head and neck pathology 57.5 30 Systematic review of the impact of germline mutations from unrelated bone marrow donors on post-allogeneic transplantation. Expert review of molecular diagnostics 64.09 31 Efficacy and safety of MEK inhibitors for NF1-associated symptomatic, inoperable plexiform neurofibromas: A systematic review and meta-analysis. PloS one 80.82 32 Eosinophilic angiocentric fibrosis in paediatric IgG4-related disease. BMJ case reports 55.2
PATIENT-FRIENDLY SUMMARY

Construction and validation of nomogram prognostic model for predicting survival in hepatoblastoma patients: a population-based study.

For education only—not personal medical advice.

Before you continue

AI-assisted research information

Neurocompute uses AI to summarize scientific papers, interpret research signals, and suggest relevant reference links. AI-generated content can be incomplete, misleading, or wrong, and generated links may be irrelevant or unavailable.

Our reviewed outputs have performed strongly to date, but past accuracy is not a guarantee. Verify summaries, scores, claims, and links against the original publication before relying on them.

This platform is for research and education only. It does not provide medical advice, diagnosis, treatment recommendations, or clinical guidance.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic